Mulsant B H, Sweet R A, Rosen J, Pollock B G, Zubenko G S, Flynn T, Begley A E, Mazumdar S, Reynolds C F
Intervention Research Center for the Study of Late-Life Mood Disorders, Department of Psychiatry, University of Pittsburgh School of Medicine, PA, USA.
J Clin Psychiatry. 2001 Aug;62(8):597-604. doi: 10.4088/jcp.v62n0804.
To conduct the first randomized study comparing the efficacy of an antidepressant alone versus an antidepressant plus a neuroleptic in the treatment of late-life psychotic depression.
The efficacy of nortriptyline plus placebo versus nortriptyline plus perphenazine was compared in 36 patients aged 50 years or older presenting with a major depressive episode with psychotic features (DSM-III-R criteria). Patients were started openly on nortriptyline treatment titrated to therapeutic levels. They were then randomly assigned under double-blind conditions to addition of perphenazine or placebo. Outcomes were compared in the 2 treatment groups using measures including the Hamilton Rating Scale for Depression (HAM-D) and the Brief Psychiatric Rating Scale (BPRS); side effects were assessed with the Geriatric Movement Disorder Assessment.
Both treatments were well tolerated. Of the 36 randomly assigned patients, 2 (1 in each group) dropped out due to treatment-related adverse effects. Four additional patients dropped out for administrative reasons. Thirty patients received nortriptyline for at least 4 weeks combined with either perphenazine (N = 14) or placebo (N = 16) for at least 2 weeks (median = 9 weeks). There was no significant difference between the completers in the 2 treatment groups when comparing their scores on the HAM-D, the BPRS, its psychoticism subscale, or any side effects measure. Rates of response (defined as resolution of both depression and psychosis) did not differ significantly in the 2 groups (nortriptyline-plus-perphenazine group, 50% vs. nortriptyline-plus-placebo group, 44%).
When treating older patients with psychotic depression, the addition of a moderate dose of a traditional neuroleptic to a tricyclic antidepressant was well tolerated but did not improve efficacy. This finding supports existing data suggesting that the pathophysiology (and thus the required treatment) of psychotic depression may be different early and late in life.
开展首项随机研究,比较单用抗抑郁药与抗抑郁药加用抗精神病药治疗老年期精神病性抑郁的疗效。
对36例年龄在50岁及以上、患有伴精神病性特征的重度抑郁发作(符合《精神疾病诊断与统计手册》第三版修订版标准)的患者,比较去甲替林加安慰剂与去甲替林加奋乃静的疗效。患者开始接受去甲替林公开治疗,并滴定至治疗水平。然后在双盲条件下将他们随机分配,分别加用奋乃静或安慰剂。使用包括汉密尔顿抑郁评定量表(HAM-D)和简明精神病评定量表(BPRS)等测量方法对两个治疗组的结果进行比较;使用老年运动障碍评估来评估副作用。
两种治疗的耐受性均良好。在36例随机分配的患者中,有2例(每组各1例)因治疗相关不良反应而退出。另有4例患者因管理原因退出。30例患者接受去甲替林治疗至少4周,并联合奋乃静(N = 14)或安慰剂(N = 16)治疗至少2周(中位数 = 9周)。在比较两个治疗组完成者在HAM-D、BPRS、其精神病性分量表或任何副作用测量指标上的得分时,未发现显著差异。两组的缓解率(定义为抑郁和精神病症状均缓解)无显著差异(去甲替林加奋乃静组为50%,去甲替林加安慰剂组为44%)。
在治疗老年精神病性抑郁患者时,在三环类抗抑郁药基础上加用中等剂量的传统抗精神病药耐受性良好,但并未提高疗效。这一发现支持了现有数据,表明精神病性抑郁的病理生理学(以及因此所需的治疗)在生命早期和晚期可能有所不同。